DRTS (Alpha Tau Medical) ROC (Joel Greenblatt) %: -197.82% (As of Mar. 2026)


DRTS Alpha Tau Medical Ltd DRTS
32 GF Score
Price $13.22
! 3 Warning Signs
View Full Analysis

What is Alpha Tau Medical ROC (Joel Greenblatt) %?

Alpha Tau Medical DRTS +4.67% 32 ROC (Joel Greenblatt) % is -197.82% as of Mar. 2026. GuruFocus rates DRTS with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,321 Biotechnology companies, Alpha Tau Medical ranks better than 56.17% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Alpha Tau Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -197.82%.

The historical rank and industry rank for Alpha Tau Medical's ROC (Joel Greenblatt) % or its related term are showing as below:

DRTS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -467.33   Med: -260.06   Max: -147.25
Current: -178.41

During the past 7 years, Alpha Tau Medical's highest ROC (Joel Greenblatt) % was -147.25%. The lowest was -467.33%. And the median was -260.06%.

DRTS's ROC (Joel Greenblatt) % is ranked better than
56.17% of 1321 companies
in the Biotechnology industry
Industry Median: -296.6 vs DRTS: -178.41

Alpha Tau Medical's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 15.30% per year.


Alpha Tau Medical  (NAS:DRTS) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Alpha Tau Medical ROC (Joel Greenblatt) % Related Terms


Alpha Tau Medical ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Alpha Tau Medical's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alpha Tau Medical ROC (Joel Greenblatt) % Chart

Alpha Tau Medical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -421.36 -324.02 -168.78 -147.25 -174.15

Alpha Tau Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -164.58 -151.64 -172.87 -184.80 -197.82

DRTS vs ORIC, OLMA, KURA: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Alpha Tau Medical's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alpha Tau Medical ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Alpha Tau Medical's ROC (Joel Greenblatt) % falls into.


DRTS
32GF Score
Alpha Tau Medical Ltd DRTS
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alpha Tau Medical ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.836) - (7.652 + 0 + 1.724)
=-4.54

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.808) - (9.247 + 0 + 0)
=-5.439

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Alpha Tau Medical for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-53.252/( ( (26.875 + max(-4.54, 0)) + (26.963 + max(-5.439, 0)) )/ 2 )
=-53.252/( ( 26.875 + 26.963 )/ 2 )
=-53.252/26.919
=-197.82 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -197.82% mean?
Alpha Tau Medical (DRTS) has a ROC (Joel Greenblatt) % of -197.82% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Alpha Tau Medical and its competitors. According to the industry distribution chart, Alpha Tau Medical ranks #579 out of 1321 companies in the Biotechnology industry, placing it in the top 43.8%.
Is Alpha Tau Medical's ROC (Joel Greenblatt) % too high?
Alpha Tau Medical's current ROC (Joel Greenblatt) % is -197.82%. Based on the distribution chart, Alpha Tau Medical ranks #579 out of 1321 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alpha Tau Medical has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's ROC (Joel Greenblatt) % compare to ORIC and OLMA?
According to the Biotechnology industry distribution chart, Alpha Tau Medical ranks #579 out of 1321 companies for ROC (Joel Greenblatt) %. This puts Alpha Tau Medical in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Alpha Tau Medical and its competitors. Alpha Tau Medical's current ROC (Joel Greenblatt) % is -197.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (DRTS) has a current ROC (Joel Greenblatt) % of -197.82%. The current ROC (Joel Greenblatt) % is -197.82%. Alpha Tau Medical's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Alpha Tau Medical (DRTS), the current ROC (Joel Greenblatt) % is -197.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alpha Tau Medical Business Description

Address Kiryat HaMada Street 5, Jerusalem, ISR, 9777605
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
32GF Score

Get the complete analysis for DRTS

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.22
Price